Literature DB >> 19697623

Ovarian cancer: lymph node metastases.

G Balbi1, M A Manganaro, A Monteverde, I Landino, C Franzese, F Gioia.   

Abstract

PURPOSE OF INVESTIGATION: To analyze pelvic and paraaortic lymph node involvement in epithelial ovarian cancer.
METHODS: Between 1995 and 2006, 60 patients with FIGO Stages II, III, IV epithelial ovarian cancer underwent surgical treatment, including systematic pelvic and paraaortic lymphadenectomy.
RESULTS: Aortic lymph node metastases were documented in 45 (75%) patients and pelvic nodal metastases in 42 (70%). The incidence of paraaortic nodal involvement was 20% (12/60) in the absence of positive pelvic nodes while the incidence of pelvic nodal involvement was 15% (9/60) in the absence of paraaortic disease; both pelvic and paraaortic lymph node involvement occurred in 55% of patients. The most frequent groups for nodal metastases are paracaval (56%), externaliliac (60%), and obturator (55%).
CONCLUSION: The rate of nodal involvement is important in ovarian cancer and there is a high prevalence of both pelvic and paraaortic lymph node metastases. For this reason bilateral pelvic and paraaortic lymphadenectomy is necessary for staging and as treatment for micrometastases, also in patients with unilateral tumors.

Entities:  

Mesh:

Year:  2009        PMID: 19697623

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  8 in total

1.  AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma.

Authors:  Jiangdong Xiang; Lina Zhou; Shuangdi Li; Xiaowei Xi; Jiarong Zhang; Yanqiu Wang; Yixia Yang; Xuelian Liu; Xiaoping Wan
Journal:  Oncol Lett       Date:  2012-01-16       Impact factor: 2.967

2.  New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination.

Authors:  Lan G Coffman; Daniela Burgos-Ojeda; Rong Wu; Kathleen Cho; Shoumei Bai; Ronald J Buckanovich
Journal:  Transl Res       Date:  2016-03-30       Impact factor: 7.012

3.  Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Authors:  Cornelia Bachmann; Robert Bachmann; Bernhard Kraemer; Sara Yvonne Brucker; Anette Staebler; Falko Fend; Ralf Rothmund; Diethelm Wallwiener
Journal:  Mol Clin Oncol       Date:  2016-08-05

4.  Nodal status--its impact on prognosis in advanced ovarian cancer.

Authors:  C Bachmann; S Bachmann; T Fehm; A Staebler; S Becker; R Rothmund; C Gardanis; E M Grischke; D Wallwiener; E F Solomayer
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

5.  The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.

Authors:  Cornelia Bachmann; Sara Y Brucker; Bernhard Kraemer; Ralf Rothmund; Anette Staebler; Falko Fend; Diethelm Wallwiener; Eva-Maria Grischke
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-05       Impact factor: 4.553

6.  Predictive value of indicator of CA125 combined with D-dimer (ICD) for lymph node metastasis in patients with ovarian cancer: A two center cohort study.

Authors:  Li Zhang; Zongyu Guan; Yi Yin; Chaoyang Ou; Hongyan Qian; Min Tang; Aiguo Shen
Journal:  J Cancer       Date:  2022-05-01       Impact factor: 4.478

7.  Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.

Authors:  Cornelia Bachmann; Robert Bachmann; Falko Fend; Diethelm Wallwiener
Journal:  J Cancer       Date:  2016-11-09       Impact factor: 4.207

8.  Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer.

Authors:  Minjun He; Yuerong Lai; Hongyu Peng; Chongjie Tong
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.